scholarly journals Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report

2021 ◽  
Vol Volume 14 ◽  
pp. 3167-3175
Author(s):  
Qian Li ◽  
Wei Liu ◽  
Kai Li ◽  
Yifu Tian ◽  
Huan Li
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Central Nervous System Lymphoma ◽  
Individualized Treatment ◽  
Secondary Central Nervous System

Primary central nervous system lymphoma: a case report

2011 ◽  
Vol 31 (7) ◽  
pp. 812-812
Author(s):  
Ai-sheng DONG ◽  
Chang-jing ZUO ◽  
Shao-yan WANG ◽  
Ming-jun GAO ◽  
Xiao-hong LI ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Central Nervous System Lymphoma

scholarly journals Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yuchen Wu ◽  
Xuefei Sun ◽  
Xueyan Bai ◽  
Jun Qian ◽  
Hong Zhu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
Central Nervous System Lymphoma ◽  
Progression Free Survival ◽  
B Cell Lymphoma ◽  
High Dose ◽  
Cns Involvement ◽  
The Central Nervous System ◽  
Secondary Central Nervous System

Abstract Background Secondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma. Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined. Methods We conducted a retrospective study to assess the feasibility of an R-MIADD (rituximab, high-dose methotrexate, ifosfamide, cytarabine, liposomal formulation of doxorubicin, and dexamethasone) regimen for SCNSL patients. Results Nineteen patients with newly diagnosed CNS lesions were selected, with a median age of 58 (range 20 to 72) years. Out of 19 patients, 11 (57.9%) achieved complete remission (CR) and 2 (10.5%) achieved partial remission (PR); the overall response rate was 68.4%. The median progression-free survival after CNS involvement was 28.0 months (95% confidence interval 11.0–44.9), and the median overall survival after CNS involvement was 34.5 months. Treatment-related death occurred in one patient (5.3%). Conclusions These single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL, further investigation is warranted.

Sign in / Sign up

Export Citation Format

Share Document